Tapestry Pharmaceuticals Inc (fka TPPHQ)

[monda2frida]

TPPHQ Tapestry Pharmaceuticals, Inc. Common Stock 3/15/2012 Plan of Bankruptcy effective. Shares have been cancelled.

http://www.otcbb.com/asp/dailylist_detail.asp?d=03/14/2012&mkt_ctg=ALL

[TeaMaw]

Have had this since 2008.... what is happening the last couple of days?? There is no news I can find.

[ToyotaMR2s]

TPPHQ .018 x .02/slowly uptrending here

[Edgar2010]

split here last month?

[ToyotaMR2s]

TPPHQ .011 x .015/nice vol. today

[ToyotaMR2s]

TPPHQ .009 x .01

[DHANA]

Is CH11 filed or not?

[DHANA]

If they file ch11, holders of our common stock may receive nothing for their shares. then what for people are still on this one?

[sfchetzel]

I heard it tanked because management was crooked!1 I dont know if they were replaced very risky to get into goto yahoo message board and there is alot oftalk about it

[jbhawk74]

Looks to be pretty quiet around here. I bought in today at .06 I have done a little research and although there doesn't seem to be anything that points to this stock getting over the .50 in the near future, I don't see anything holding this back from maybe .20 in the next couple months

[BIG BALLER]

Be careful doggie,,,I'm thinking it'll test a nickle here maybe grab some on the dip?

)

EZ!!!!

[GoldenZ]

lets see htis go back to .20

[kittycattttt]

WHOOOOOOPPPIIIIIIEEEEEE? I dont mean Goldberg either?lol

[kittycattttt]

Some doesnt want it to break .098, 2bad cause here we go!

[kittycattttt]

22% up just gettin started

[kittycattttt]

:>} VOL looks to be huge 2day!

[kittycattttt]

:>}

[Lex_Luthor]

Any ideas on why it tanked??

[kittycattttt]

All indicators point up! G luck chuck? Buy now or else be stupid lol!

[kittycattttt]

next week, KABOOOOOMMMM!!!!!!!

[kittycattttt]

But what do i know

[kittycattttt]

1 year target 5$

[lady sofia]

bought some at 0.04! weee!

[ScovilleUnits]

I see.... http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5448169

The Company has taken the following steps:

· Retained bankruptcy counsel and initiated steps to file for bankruptcy protection under Chapter 11 of the Bankruptcy Code.

· Reduced it workforce from 34 to 12 persons.

· Attempted to sell its investment in ChromaDex, Inc., a privately held supplier of phytochemical reference standards for the nutraceutical, dietary supplement and functional food industries of which we are a shareholder. The carrying value of the our investment in ChromaDex is $459,000 as of September 27, 2007.

· Taken other steps to reduce expenses, including closing down facilities that are no longer needed based upon our reduced level of operations.

· Determined that no additional sites for clinical trials for TPI 287 will be initiated and that patients who are not yet screened will not be put on study.

· Determined to continue efforts to sell or finance the Company or to sell or license our intellectual property.

There are significant risks and obstacles that could prevent any financing or sale of the Company or the licensing of its intellectual property. They include:

· We may have insufficient resources to survive until a transaction is consummated.

· The value of our product candidate and related intellectual technology could deteriorate in the absence of sufficient resources committed to their development.

· Our common stock is concentrated in the hands of a small number of institutional investors, and any sale or financing outside of bankruptcy would likely require their cooperation, which cannot be assured even if a willing buyer or investor is found.

· Our value and that of our principal assets lies almost entirely in our clinical trial data and patent and intellectual property position. We are still in the early stages of clinical development of our product candidate and are still developing our patent position. Significant uncertainties relating to the success of clinical trials and to the protection of intellectual property exist that have frustrated our efforts to obtain additional financing or to sell the Company and that may deter any future potential buyer, investor or licensing or development partner.

· A number of possible buyers or investors have determined not to proceed with an acquisition or financing of the Company, as a result of one or more of the foregoing issues, among others.

We believe that the Company has very few options now other than filing for bankruptcy and attempting to reorganize or to sell our assets in a bankruptcy proceeding. In such a circumstance, holders of our common stock may receive nothing for their shares.

[ScovilleUnits]

WTF???

Date Open High Low Close Volume Change Change %

2/13/08 0.049 0.055 0.036 0.0389 2,520,403 -0.0021 -5.12%

2/12/08 0.189 0.189 0.04 0.041 4,768,466 -0.199 -82.92%

2/11/08 0.29 0.29 0.22 0.24 12,340 -0.01 -4.00%
2/8/08 0.2402 0.28 0.2203 0.25 64,914 -0.01 -3.85%
2/7/08 0.2502 0.28 0.2303 0.26 17,533 – –
2/6/08 0.26 0.29 0.24 0.26 17,480 -0.01 -3.70%
2/5/08 0.25 0.28 0.25 0.27 3,640 0.002 0.75%
2/4/08 0.26 0.2798 0.26 0.268 5,700 -0.0117 -4.18%
2/1/08 0.2602 0.2898 0.26 0.2797 6,260 -0.0001 -0.04%


--------------------------------------------------------
TPPH: Receives Non-Compliance Notice from Nasdaq re Minimum Bid Price

Friday , December 21, 2007 15:59ET

By Fain Hughes, [e-mail]

Tapestry Pharmaceuticals, Inc. (TPPH) received a notice from the Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Tapestry was therefore not in compliance. Tapestry has until June 16, 2008, which is 180 calendar days from December 18, 2007, to regain compliance.

[analogdog]

Loading.

[analogdog]

Not bottom.

[rattlewatch]

Thanks albundy,have heard of the hacking problems in recent months and confirmed with my Scottrade broker.The link to Apilgrim has a list of companies that were involved,which i haven't seen.

The insider buys are for real,and can be confirmed at the SEC link in the earlier post.In general insiders can buy fairly close to news/revenue increase.It is usually when they sell they have SEC trouble.With this recent activity ,something should be coming,just a matter of when.

From the last report ,only 16.3M O/S.Was just trying to find out what caused the major pps drop.

PEEEACE

[albundy]

you could start by checking their filings to see if they issued any shares since. one other possible contributing factor - http://www.investorshub.com/boards/read_msg.asp?message_id=17690929&txt2find=tpph+

[rattlewatch]

Hi Kriskringle,

Ran across some insider buying on TPPH,which has led me here.There have been a total of six insider buys since Oct 06 for a total of 170K shares approx,in the $1.50-$1.75 range. They also have some interesting Options which vest when the share price is up certain percentages of pps.(below)

Have a ? for you if you don't mind.Any idea what happened to this company now that it is trading so much lower then 5 years ago?It was $130 per share in 02.

Thanks
rattlewatch

"1. This option vests as follows: 1/6 when the 20 trading day average of the closing sale price of Tapestry common stock equals or exceeds 130% of the exercise price of the option; 1/6 when such average equals or exceeds 160% of the exercise price; 1/6 when such average equals or exceeds 190% of the exercise price; 1/6 when such average equals or exceeds 220% of the exercise price; 1/6 when such average equals or exceeds 250% of the exercise price;1/6 when such average equals or exceeds 300% of the exercise price. Any unvested shares vest automatically five years from the date of grant."

http://www.sec.gov/cgi-bin/browse-edgar?type=&dateb=&owner=only&count=40&action=getc...

[kriskringle]

Tapestry to Downsize and Focus on TPI 287 Clinical Program
BOULDER, Colo., July 25 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH), a company focused on the development of proprietary therapies for the treatment of cancer, announced today that it is significantly reducing its cash burn and focusing its primary effort on advancing TPI 287, its lead anticancer compound, through the clinic.

Tapestry expects savings from this downsizing, and other cost saving measures, to total approximately $7.4 million through the end of 2006. The Company expects to eliminate 14 positions (about 30% of its workforce) including executive and non-executive employees and consultants in all areas of operations. There will be a one-time cost of approximately $270,000 to implement this downsizing.

'We expect this focusing of the Company to direct the majority of our resources to our lead clinical programs. All other programs will be scaled back to accomplish this goal,' commented Leonard P. Shaykin, Chairman and Chief Executive Officer of Tapestry Pharmaceuticals. 'With respect to TPI 287, patient recruitment is on schedule. We are pleased with the compound's performance to date. We expect to initiate a second Phase I clinical trial for TPI 287, on an alternative dosing regimen before the end of the year and to initiate our first Phase II clinical study around mid-year 2006.'

[kriskringle]

Current pps .46 - 6 months from now, it will be over $3.00

[kriskringle]

TPPH is the next listed penny biotech to skyrocket!